| Novartis Pharma Schweiz AG - Optaflu, Injektionssuspension | | 58271 | | 02 | | Optaflu | | Injektionssuspension | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 18.07.2014 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus-Stamm A/California/7/2009 (H1N1)-like: reassortant virus A/Brisbane/10/2010) 15 µg, haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Texas/50/2012 (H3N2)-like: reassortant virus NYMC X-223A) 15 µg, haemagglutininum influenzae B (Virus-Stamm B/Massachusetts/2/2012) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia, q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | Injection suspension | | | | | | Active Agent | Dose |
|---|
| | 15 µg | | | 15 µg | | | 15 µg |
|
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| No entries have been found. |
|
|
